Executive Summary
HHS BARDA's $55.5M cost-plus-fixed-fee contract to Public Health Vaccines LLC for Marburg vaccine R&D (potential $101M with options) provides long-term revenue stability through 2028 for this small disadvantaged biotech. With 33% ($18.4M) outlayed since 2019, the award signals government priority on biothreat vaccines amid execution risks. Investors gain a high-confidence bullish entry on stable funding with $46M upside from options.
Tracking the trend? Catch up on the prior HHS & Healthcare Contracts Intelligence digest from January 05, 2026.
Investment Signals(1)
- BARDA long-term vaccine R&D funding(HIGH)▲
$55.5M obligation (potential $101M) through 2028 offers revenue stability for small biotech.
Risk Flags(2)
- Execution[HIGH RISK]▼
R&D uncertainty in health services (PSC AN13) despite cost-plus structure
- Execution[MEDIUM RISK]▼
Only 33% ($18.4M of $55.5M) outlayed after 7 years
Opportunities(1)
- ◆
$46M unexercised options could nearly double contract value to $101M
Sector Themes(1)
- ◆
Full-and-open competition award to small disadvantaged business underscores sustained HHS funding for NAICS 541714 biotech R&D.
Watch List(1)
- 👁
{"entity"=>"Public Health Vaccines LLC", "reason"=>"$55.5M BARDA contract with $46M options and 33% outlay signals revenue potential through 2028", "trigger"=>"Outlay acceleration >$5M/quarter or option exercises"}
Get daily alerts with 1 investment signals, 2 risk alerts, 1 opportunities and full AI analysis of all 1 filings
🇺🇸 More from United States
View all →March 25, 2026
US Pre-Market SEC Filings Roundup — March 25, 2026
US Pre-Market SEC Filings Roundup
March 24, 2026
US Merger & Acquisition SEC Filings — March 24, 2026
US Merger & Acquisition SEC Filings
March 24, 2026
US Corporate Board Director Changes SEC Filings — March 24, 2026
US Corporate Board Director Changes SEC Filings
March 24, 2026
US Executive Officer Management Changes SEC — March 24, 2026
US Executive Officer Management Changes SEC